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Abstract: The use of targeted therapies for the treatment of thymic
malignancies is documented in the literature. However, only a few
drugs have undergone evaluation in phase II trials. Most of the
evidence for the benefit of biologic therapies for thymic malignan-
cies is in the form of case reports and small case series. No major
activity has been observed with any agent so far, likely due to the
lack of selection of patients for targeted therapies and the small
numbers studied. A better understanding of the biology of these
tumors will be essential in furthering the field.
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Complete surgical resection is vital for the successfulmanagement of thymic malignancies. However, thymo-
mas can recur in 10 to 30% cases after an R0 resection.
Chemotherapy and radiation therapy play an important role in
the management of recurrent disease. The search for biologic
agents in thymoma and thymic carcinoma has yielded disap-
pointing results so far.1–4 Although overexpression of the
epidermal growth factor receptor (EGFR) and c-KIT can be
demonstrated by immunohistochemistry (IHC), the paucity of
drug-sensitizing mutations in these genes explains the lack of
efficacy of targeted therapies in patients with thymic malig-
nancies. In this chapter, we present data from case reports and
clinical trials that have explored the role of biologic therapy
in thymoma and thymic carcinoma.
EGFR Inhibitors
Kurup et al.5 reported results of a phase II study of
gefitinib in advanced thymic malignancies. Twenty-six pa-
tients with previously treated thymic malignancies were en-
rolled (19 thymomas and 7 thymic carcinomas) and treated
with gefitinib at a dose of 250 mg orally once daily. Each
treatment cycle was defined as 28 days, and patients were
treated to a maximum of eight cycles. Mutational analysis for
EGFR and KRAS mutations was performed in five cases.
Only one partial response (PR) was noted among 26 patients.
There was no complete response (CR). Fourteen patients had
stable disease (SD), including six patients with SD lasting for
more than 4 months. Grade 3/4 adverse events included
dyspnea (12%), fatigue (4%), anemia/thrombocytopenia
(4%), and myocardial infarction (4%). The median time to
progression was 4 months (1–17 months). None of the five
samples evaluated by DNA sequencing showed evidence of
EGFR or KRAS mutations.
There have been isolated case reports of response of
advanced thymoma to erlotinib therapy.6 A phase II trial was
conducted to evaluate the combination of erlotinib and bev-
acizumab in patients with recurrent thymoma and thymic
carcinoma. Eighteen previously treated patients with ad-
vanced thymic malignancies were treated with erlotinib 150
mg orally once daily and bevacizumab 15 mg/kg intrave-
nously (IV) on day 1 of a 3-week cycle.7 Responders or
patients with SD after two cycles continued to receive treat-
ment until progression or development of unacceptable tox-
icity. No responses were seen with this regimen although 11
patients (60%) achieved SD. There were no grade 4 toxicities.
Grade 3 toxicities included acneiform rash (11%), dyspnea
(11%), fatigue (6%), pericardial tamponade (6%), and aortic
insufficiency (6%). Median survival time had not been
reached at the time that the results were reported.
No prospective studies evaluating the role of cetuximab
in thymic malignancies have been reported to date. However,
there have been a handful of case reports that have docu-
mented responses of advanced thymoma to cetuximab. Palm-
ieri et al.8 reported PRs in two patients with previously
treated thymoma. The tumors showed EGFR protein expres-
sion detected by IHC. Farina et al. described one patient with
a previously treated B2 thymoma who achieved a PR after 6
weeks of treatment with cetuximab. Although the tumor
demonstrated overexpression of EGFR by IHC, no EGFR
amplification or mutation was detected in this tumor.9 Cur-
rently, there is an ongoing phase II study evaluating the
combination of cetuximab with chemotherapy (cisplatin,
doxorubicin, and cyclophosphamide) in patients with stage
III to IVA thymoma before surgical resection (ClinicalTrials.
gov Identifier: NCT01025089).
c-KIT Inhibitors
A case of metastatic poorly differentiated epidermoid
carcinoma of the thymus responding to imatinib at a dose of
400 mg orally daily has been described in the literature.10
This patient harbored an activating mutation in exon 11 of the
KIT gene (V560del). However, prospective studies evaluating
imatinib for treatment of thymic malignancies have yielded
disappointing results. Salter et al.11 reported results of a pilot
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study of imatinib in patients with previously treated thymic
carcinoma that stained positive for either c-KIT or platelet-
derived growth factor receptor (PDGFR) by IHC. Eleven
patients were enrolled and treated with imatinib at a dose of
600 mg orally daily on a 21-day cycle. No objective re-
sponses were seen. However, three patients (27%) achieved
SD as their best response with a median duration of SD of 6
weeks. No grade 4 toxicities were noted in this study. Grade
3 toxicities related to treatment included dyspnea (n 1) and
hyponatremia (n  1).
A phase II study of imatinib at a dose of 600 mg orally
daily was conducted in seven patients with thymic malignan-
cies, including two B3 thymomas and five thymic carcino-
mas.12 The dosage was increased to 800 mg daily if there was
evidence of disease progression. Three patients had received
no prior chemotherapy. No objective responses were seen
with imatinib monotherapy. Two patients (29%) achieved
disease stabilization and five patients had progressive disease.
The median time to progression was 2 months and median
survival was 4 months. Grade 3/4 toxicities included emesis
(n  1) and depression (n  1). Three tumor samples were
analyzed for mutations in the c-KIT or PDGFRA genes, and
no mutations were detected.
Histone Deacetylase Inhibition
Histone deacetylases (HDACs) are enzymes that are
involved in the post-translational modification of histones and
thereby exert an influence on DNA packaging and chromatin
remodeling. HDAC inhibition can alter gene expression and
induce apoptosis. In a phase I study of the HDAC inhibitor
belinostat, a patient with heavily pretreated metastatic thy-
moma had disease stabilization that lasted for 17 months.13 A
patient with previously treated thymic carcinoma on another
phase I study of the HDAC inhibitor MGCD0103 experi-
enced disease stability for 18 weeks.14 Based on this data, a
phase II study of belinostat was conducted in patients with
thymoma or thymic carcinoma who had recurrent or refrac-
tory disease after receiving at least one platinum-containing
chemotherapy regimen.15 Twenty-two patients had been en-
rolled as of December 2008 (14 thymomas and 8 thymic
carcinomas). Belinostat was administered at a dose of 1000
mg/m2/d IV for 5 days every 3 weeks (beyond 12 cycles of
therapy: every 4 weeks). Of 21 patients evaluable for re-
sponse, there were 2 PRs (both thymomas), 13 SD, and 6 PD.
Treatment was well tolerated. The most common adverse
event was nausea, and it was well controlled with prophylac-
tic antiemetics.
Because belinostat showed some activity in patients
with thymoma, an ongoing phase 1/2 study is evaluating it
in combination with cytotoxic chemotherapy (cisplatin,
doxorubicin, and cyclophosphamide) in chemotherapy-
naïve patients with advanced or recurrent thymic malig-
nancies (ClinicalTrials.gov Identifier: NCT01100944).
Treatment consists of belinostat administered as a continuous
IV infusion over 48 hours on days 1 and 2, with cisplatin
given on day 2, doxorubicin administered on days 2 and 3,
and cyclophosphamide given IV on day 3 of a 21-day cycle.
Doses per cycle at dose level 1 are 1000, 50, 50, and 500
mg/m2, respectively. Two patients have been enrolled on
study so far. Treatment has been fairly well tolerated. The
most common adverse event has been nausea that has been no
worse than that associated with chemotherapy alone.
OTHER TARGETED THERAPIES
Sorafenib
Sorafenib is a multikinase inhibitor that inhibits RAF,
VEGFR, PDGFR, c-KIT, and p38. There are a handful of
case reports describing responses to sorafenib in patients with
previously treated metastatic thymic carcinoma. In one case,
a patient was found to have a missense mutation in exon 17
(D820E) of the c-KIT gene that was detected by direct
sequencing. He achieved a PR 8 weeks after initiation of
sorafenib therapy at a dose of 200 mg orally twice daily.16 At
the time of reporting, the patient continued to demonstrate a
PR after 15 months of therapy. An identical mutation has
been identified in patients with gastrointestinal stromal tumor
that is unresponsive to treatment with imatinib mesylate. A
second case of sorafenib-responsive thymic carcinoma was
reported by Li et al.17 In this case, the patient had disease
progression despite receiving three prior regimens of cyto-
toxic chemotherapy. He was then treated with sorafenib at a
dose of 400 mg orally twice daily and achieved disease
stabilization that had lasted for more than 9 months at the
time of reporting of results. Although no mutational analysis
was performed in this case, the tumor did show strong
immunohistochemical expression of KIT, p53, and vascular
endothelial growth factor (VEGF).
IMC-A12 (Cixutumumab)
Zucali et al.18 conducted a retrospective analysis of a
surgical series of 132 patients with thymic epithelial tumors
to determine the extent of insulin-like growth factor-1 recep-
tor (IGF-1R) expression by IHC. Among 111 samples that
were evaluable for IGF-1R IHC staining, 22 cases (20%)
were found to be positive. IGF-1R expression was signifi-
cantly less common among World Health Organization type
A, AB, and B1 thymomas compared with B1/B2, B2, B2/B3,
B3, and C subtypes (3.4 versus 37.2%, p  0.0001).
In a phase I dose escalation study of the anti-IGF-1R
monoclonal antibody, CP-751,871, a patient with metastatic
thymoma demonstrated a 10% reduction in tumor size with
disease stabilization lasting for more than 1 year.19
Based on this data, a phase II study was designed to
evaluate cixutumumab, a monoclonal antibody directed
against IGF-1R, in patients with unresectable thymoma or
thymic carcinoma who have progressed after receiving at
least one platinum-containing chemotherapy regimen.20
Cixutumumab is administered at a dose of 20 mg/kg on day
1 of a 21-day cycle until disease progression or development
of intolerable adverse effects. As of December 2009, 13
patients had enrolled at the National Cancer Institute includ-
ing five patients with thymoma and eight patients with thymic
carcinoma. A median of 3 cycles of treatment had been
administered (range, 1–7). The best response was SD is eight
patients (four thymoma and four thymic carcinoma); five
patients experienced disease progression. Treatment has been
well tolerated. Frequent adverse events include asymptomatic
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hyperglycemia and pain at the site of metastatic disease that
is responsive to nonsteroidal anti-inflammatory drugs.
Octreotide
The Eastern Cooperative Oncology Group conducted a
phase II trial of octreotide alone or with prednisone in
patients with advanced, unresectable, octreotide scan-positive
thymoma and thymic carcinoma.21 There were 38 assessable
patients (32 thymoma, 5 thymic carcinoma, and 1 thymic
carcinoid) treated with octreotide at a dose of 0.5 mg subcu-
taneously three times a day for a maximum of 1 year. An
assessment for response was made at 2 months. Those pa-
tients who were responding continued with octreotide ther-
apy, and patients with progressive disease were taken off
treatment. For patients with SD, prednisone therapy was
started at a dose of 0.6 mg/kg/d along with octreotide for a
maximum of 1 year. Two patients had stage III disease, 34
patients had stage IV disease, and staging was incomplete for
2 patients. Responses included 2 CRs (5%) and 10 PRs (26%)
for an overall response rate of 32% (95% confidence interval,
17.5–48.7%). Fourteen patients (37%) had SD and 12 pa-
tients (32%) had PD. All 38 patients were initially treated
with octreotide alone, and 4 PRs (11%) were seen. Pred-
nisone was added to octreotide for 21 patients, and 2 CRs and
6 PRs were seen with the combination. Toxicities included
one grade 5 and seven grade 4 adverse events. One patient
treated with the combination had a grade 5 infection not
associated with neutropenia. Three patients treated with oct-
reotide alone and four patients treated with the combination
had grade 4 metabolic abnormalities and dyspnea. Grade 4
hematological abnormalities included anemia and leucopenia.
Overall, the combination of octreotide and prednisone exhib-
ited modest activity and could be considered for the treatment
of recurrent disease in selected patients.
Sunitinib and SU014813
Sunitinib is a multikinase inhibitor that targets
VEGFR1–3, PDGFR, c-KIT, FLT3, colony stimulating fac-
tor-1 (CSF1), and the RET receptor. Strobel et al.22 treated
four patients with refractory thymic carcinoma with sunitinib
at doses of 25 to 50 mg/d. In three cases, tumor samples were
available to perform molecular analyses, which showed acti-
vation of multiple receptor tyrosine kinases including
PDGFR- and VEGF3. Three patients demonstrated a PR
with sunitinib therapy lasting between 2 and 18 months,
and the fourth patient had SD lasting 22 months. Overall
survival with sunitinib therapy in this series of patients was 4
to 40 months.
SU014813 is an orally administered multikinase inhib-
itor that targets VEGFRs, PDGFRs, KIT, and FLT-3.23 A
phase I study of SU014813 was conducted in patients with
advanced solid tumors using two different dosing schedules
(escalating doses administered for 4 weeks with a 1 week
break in therapy or doses of 100 or 150 mg administered
using a continuous dosing schedule). Seventy-seven patients
were enrolled with chemorefractory solid tumors including
four patients with thymoma. Adverse events included fatigue
(64%), diarrhea (61%), nausea (44%), anorexia (43%), and
emesis (42%). The most common hematological adverse
event was thrombocytopenia (22%). Twelve patients had an
objective response to treatment including two patients with
thymoma with PRs that lasted 15.3 and 9 months, respec-
tively. Twenty-four patients had SD including five patients
with disease stabilization lasting more than 12 months.
PHA-848125-AC
Decreased expression of cell cycle proteins such as p21
and p27 predicts for poor response to neoadjuvant chemo-
therapy in invasive thymoma.24 p21 and p27 are natural
inhibitors of cyclin-dependant kinases. In addition, the pat-
tern of expression of the neurotrophin receptors TRKA and
p75 can be correlated with the World Health Organization
subtype of thymic malignancies.25 PHA-848125 is an orally
administered potent inhibitor of the cyclin-dependant kinase
2/cyclin A complex and TRKA. In an ongoing phase I study,
two of three patients with thymic malignancies (type B3 and
C histologies) demonstrated a PR after 10 and 6 months of
treatment, respectively, at a dose of 150 mg/d. Based on
these results, an ongoing multicenter phase II study is
evaluating PHA-848125-AC in patients with thymic car-
cinoma (ClinicalTrials.gov Identifier: NCT01011439). The
study drug is administered at a flat dose of 150 mg once daily
for 7 consecutive days of a 2-week cycle. The primary end
point is the progression-free survival rate at 3 months.
Saracatinib
Wakelee et al.26 reported results of a phase II study of
the Src inhibitor saracatinib (AZD0530) in previously treated
patients with advanced thymic malignancies. Saracatinib was
administered orally at a dose of 175 mg once daily, and
treatment was repeated in 28-day cycles. Twenty-one patients
were enrolled on the study, including 14 patients with thy-
moma and 7 patients with thymic carcinoma. Nineteen pa-
tients were evaluable for response. The best response was SD
in eight patients; no objective responses were seen. Treatment
was generally well tolerated. Grade 3/4 adverse effects in-
cluded one case each of dyspnea, neutropenia, and anemia.
According to prespecified criteria, the study was terminated
after no clinical activity was seen in the first 13 patients with
thymoma who were enrolled on study.
CONCLUSIONS
So far, targeted therapy has yielded modest results in
the treatment of thymic malignancies in patients who have
failed chemotherapy. Anecdotal reports of response to bio-
logic agents have been associated with the presence of rare
mutations in specific genes. At present, targeted therapy
cannot be recommended for the routine management of
patients with thymoma and thymic carcinoma. As data be-
come available from ongoing systematic analyses of genetic
aberrations in thymic tumors, it is possible that newer targets
will be uncovered in the future, which can be treated with
biologic therapy.
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